mesalamine has been researched along with Latent Tuberculosis in 5 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Latent Tuberculosis: The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dussouillez, G | 1 |
| Zayet, S | 1 |
| Kone, D | 1 |
| Royer, PY | 1 |
| Toko-Tchuindzie, L | 1 |
| Ruyer, O | 1 |
| Gendrin, V | 1 |
| Taxonera, C | 1 |
| Ponferrada, Á | 1 |
| Bermejo, F | 1 |
| Riestra, S | 1 |
| Saro, C | 1 |
| Martín-Arranz, MD | 1 |
| Cabriada, JL | 1 |
| Barreiro-de Acosta, M | 1 |
| de Castro, ML | 1 |
| López-Serrano, P | 1 |
| Barrio, J | 1 |
| Suarez, C | 1 |
| Iglesias, E | 1 |
| Argüelles-Arias, F | 1 |
| Ferrer, I | 1 |
| Marín-Jiménez, I | 1 |
| Hernández-Camba, A | 1 |
| Bastida, G | 1 |
| Van Domselaar, M | 1 |
| Martínez-Montiel, P | 1 |
| Olivares, D | 1 |
| Alba, C | 1 |
| Gisbert, JP | 1 |
| Mantzaris, GJ | 2 |
| Tsironikos, D | 1 |
| Tzanetakou, X | 1 |
| Grispou, E | 1 |
| Karatzas, P | 1 |
| Kalogeropoulos, I | 1 |
| Papamichael, K | 2 |
| Onal, IK | 1 |
| Alizadeh, N | 1 |
| Sargin, ZG | 1 |
5 other studies available for mesalamine and Latent Tuberculosis
| Article | Year |
|---|---|
[Tuberculous liver abscess, anti-TNF alpha, and immune reconstitution inflammatory syndrome].
Topics: Adalimumab; Adult; Antirheumatic Agents; Antitubercular Agents; Drug Substitution; Drug Therapy, Com | 2020 |
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Immunosuppressive Agent | 2017 |
The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Immunotherapy; Inflammatory Bowel Diseases; Latent | 2015 |
Author's reply to Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: disease activity as an influencing factor.
Topics: Female; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Latent Tuberculosis; Male; Me | 2016 |
Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: Disease activity as an influencing factor.
Topics: Female; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Latent Tuberculosis; Male; Me | 2016 |